Thalidomide-PEG4-NH2 hydrochloride

Background Introduction

Thalidomide-PEG4-NH2 hydrochloride is a specialized E3 Ligase Ligand-Linker Conjugate designed for use in targeted protein degradation technologies such as PROTACs (Proteolysis Targeting Chimeras). This conjugate combines the cereblon (CRBN) binding ligand, thalidomide, with a hydrophilic polyethylene glycol (PEG4) linker ending in an amine functional group, facilitating customized conjugation. Its salt form improves solubility and handling for research and development purposes.

Mechanism

The mechanism of Thalidomide-PEG4-NH2 hydrochloride is centered around harnessing the power of the ubiquitin-proteasome system for specific protein degradation. Thalidomide acts as an E3 ligase ligand, recruiting the CRBN component of the CRL4 E3 ubiquitin ligase complex. When the PEG4-NH2 linker is covalently attached to a ligand targeting a protein of interest, the resulting PROTAC molecule brings the target protein in proximity to the E3 ligase. This close association induces ubiquitination and subsequent proteasomal degradation of the target protein in cells, representing a targeted and reversible alternative to gene editing.

Applications

Thalidomide-PEG4-NH2 hydrochloride is widely used in the development of PROTACs and molecular glue degraders. Its modular design enables researchers to construct customized bifunctional molecules to degrade pathogenic proteins implicated in cancer, neurodegenerative diseases, and other conditions. Additionally, its application extends to the study of E3 ligase biology, optimization of linker composition in protein degradation technology, and the synthesis of tool compounds for mechanism-of-action studies and drug target validation.

• Flexible PEG4 linker improves solubility and cellular permeability for efficient PROTAC design.
• Amine-terminated structure facilitates rapid conjugation with diverse warheads for targeted protein degradation.

Thalidomide-PEG4-NH2 hydrochloride serves as a versatile E3 Ligase Ligand-Linker Conjugate in PROTACs, facilitating targeted protein degradation by bridging target proteins with E3 ligases. The following provides a detailed description of this molecule, including the linker, ligand, and selection of target protein ligands.

Linker: The linker in Thalidomide-PEG4-NH2 hydrochloride is a polyethylene glycol (PEG) chain with four ethylene glycol units, offering moderate flexibility and hydrophilicity. This non-cleavable linker enhances solubility and cellular permeability, crucial for effective PROTAC function.

Ligand: The ligand component is derived from thalidomide, a well-characterized E3 ligase binder. Its structural features include a glutarimide ring, which efficiently binds to the cereblon E3 ligase, facilitating ubiquitination and subsequent degradation of target proteins.

Reactive Site: The reactive site in this molecule is the terminal amine group (NH2), which couples with the target protein ligand through amide bond formation or other nucleophilic substitution reactions, providing robust and stable conjugation.

Recommended Target Protein Ligand: A suitable warhead for Thalidomide-PEG4-NH2 hydrochloride is one containing an electrophilic functional group, such as a carbonyl or sulfonyl chloride. These warheads are advantageous for forming stable covalent bonds with the reactive amine, enabling precise targeting and degradation of disease-related proteins in experimental research settings.